Antibodies News and Research

RSS

SARS-CoV-2 antibodies and COVID symptoms can last at least 3 months

Recent research published as a preprint on the medRxiv preprint server, Elizabeth T. Cirulli et al., studies the self-reported short and long-term symptoms in a large general adult population cohort.

13 Oct 2020

Why blood type O might lower risk for SARS-CoV-2 infection

The author hypothesizes that people with non-O blood groups may have highest contact with the SARS-CoV-2 virus via the formation of in intermediate structure, resulting in possibly higher infection rates and more severe symptoms.

12 Oct 2020

Understanding the production of memory B cells and immune responses

The current COVID-19 climate has made vaccines, antibodies, and immune responses topics of everyday conversation.

12 Oct 2020

Dynamic map reveals how cells fight microbes and preserve memory for future infections

Researchers have charted the activity of tens of thousands of genes in mouse immune cells over the course of an infection.

12 Oct 2020

Newly identified coronavirus epitopes induce robust antibody responses

Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.

12 Oct 2020

COVID-19-positive mothers rarely transmit the virus to their newborns

Mothers with SARS-CoV-2 infection rarely transmit the virus to their newborns when basic infection-control practices are followed, according to a new study by researchers at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children's Hospital.

12 Oct 2020

Scientists develop new type of precise therapeutic vaccine against leukemia

Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

12 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

Study shows how mutations in VAV1 gene may promote T-cell tumors in experimental mice

Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

CHLA investigator receives $3.4 million research grant to study rotavirus vaccine

Rotavirus (RV) is an extremely contagious viral infection and the most common cause of diarrhea in infants and children worldwide.

9 Oct 2020

Too little sugar is the cause of perforated bones

Bone marrow cancer is currently an incurable disease that affects about 400 people in Norway every year. Professor Therese Standal at NTNU has now found an important reason for bone destruction in people with this disease.

9 Oct 2020

Antibody cocktail may offer clinical benefit in both prevention and treatment of COVID-19

In June, two studies in Science reported an antibody cocktail against SARS-CoV-2 developed from studies in humanized mice and recovering patients. The two antibody cocktail was designed to bind the virus to reduce the risk of a drug-resistant form emerging.

9 Oct 2020